Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Arthritis, Juvenile × Etanercept × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vasculitis 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Metabolic Syndrome 1 Lung Neoplasms 1 Inflammation 1 Granulomatosis with Polyangiitis 1 Bone Neoplasms 1 Arthritis, Juvenile 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03780959 2019-08-02

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Amgen

Phase 2/3 Completed

69 enrolled 11 charts

Arthritis, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon ⚡